Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Sickle Cell Disease With Vaso-Occlusive Crisis - Overview
Sickle Cell Disease With Vaso-Occlusive Crisis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Sickle Cell Disease With Vaso-Occlusive Crisis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Sickle Cell Disease With Vaso-Occlusive Crisis - Companies Involved in Therapeutics Development
Asklepion Pharmaceuticals LLC
Chugai Pharmaceutical Co Ltd
Cyclerion Therapeutics Inc
Global Blood Therapeutics Inc
GlycoMimetics Inc
Hartis Pharma SA
KM Biologics Co Ltd
NicOx SA
Novartis AG
Prolong Pharmaceuticals LLC
Sickle Cell Disease With Vaso-Occlusive Crisis - Drug Profiles
apadamtase alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crizanlizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crovalimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GMI-1687 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HRT-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
inclacumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
L-Citrulline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
proxcinod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
olinciguat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sanguite - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sickle Cell Disease With Vaso-Occlusive Crisis - Dormant Projects
Sickle Cell Disease With Vaso-Occlusive Crisis - Discontinued Products
Sickle Cell Disease With Vaso-Occlusive Crisis - Product Development Milestones
Featured News & Press Releases
Apr 16, 2021: TGA provides update on Adakveo
Dec 07, 2020: GlycoMimetics announces presentation of preclinical data on GMI-1687 at the ASH meeting
Nov 19, 2020: Novartis announces presentation on Adakveo at 62nd American Society of Hematology (ASH) Annual Meeting & Exposition
Oct 30, 2020: Novartis sickle cell medicine Adakveo approved in Europe to prevent recurrent vaso-occlusive crises
Oct 26, 2020: New pediatric and secondary endpoint data from rivipansel phase 3 RESET trial presented at The Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) Meeting
Jun 12, 2020: GlycoMimetics announces to present preclinical data on GMI-1687 at Sickle Cell Meeting
Dec 20, 2019: Novartis wins Medicaid approval for new sickle cell drug in key US states
Nov 18, 2019: FDA approves Novartis’ Adakveo for sickle cell disease patients
Jul 16, 2019: FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
Jan 09, 2018: Prolong Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference
Dec 13, 2017: Prolong Pharma Announces Completion of Enrollment in Phase II Study of SANGUITE in the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis in an Ambulatory Setting
Nov 08, 2017: Prolong Pharmaceuticals to Present New Research on SANGUITE, an Investigatiol Treatment Under Evaluation for Vaso-Occlusive Crisis in Patients with Sickle Cell Disease, at ASH Annual Meeting
Feb 01, 2017: A multiple drug approach to preventing sickle cell crisis
Aug 19, 2013: Selexys Pharmaceuticals Initiates SUSTAIN Phase 2 Clinical Trial in Sickle Cell Patients with Pain Crises
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Sickle Cell Disease With Vaso-Occlusive Crisis, 2021
Number of Products under Development by Companies, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development for Sickle Cell Disease With Vaso-Occlusive Crisis, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Sickle Cell Disease With Vaso-Occlusive Crisis - Pipeline by Asklepion Pharmaceuticals LLC, 2021
Sickle Cell Disease With Vaso-Occlusive Crisis - Pipeline by Chugai Pharmaceutical Co Ltd, 2021
Sickle Cell Disease With Vaso-Occlusive Crisis - Pipeline by Cyclerion Therapeutics Inc, 2021
Sickle Cell Disease With Vaso-Occlusive Crisis - Pipeline by Global Blood Therapeutics Inc, 2021
Sickle Cell Disease With Vaso-Occlusive Crisis - Pipeline by GlycoMimetics Inc, 2021
Sickle Cell Disease With Vaso-Occlusive Crisis - Pipeline by Hartis Pharma SA, 2021
Sickle Cell Disease With Vaso-Occlusive Crisis - Pipeline by KM Biologics Co Ltd, 2021
Sickle Cell Disease With Vaso-Occlusive Crisis - Pipeline by NicOx SA, 2021
Sickle Cell Disease With Vaso-Occlusive Crisis - Pipeline by Novartis AG, 2021
Sickle Cell Disease With Vaso-Occlusive Crisis - Pipeline by Prolong Pharmaceuticals LLC, 2021
Sickle Cell Disease With Vaso-Occlusive Crisis - Dormant Projects, 2021
Sickle Cell Disease With Vaso-Occlusive Crisis - Discontinued Products, 2021